Clinical Trial Failure and Uncertainty: The success of Galectin Therapeutics' lead drug candidate, belapectin, is not guaranteed in ongoing or future clinical trials. Trial results may not be sufficient for regulatory approval, or unexpected safety issues could emerge, leading to significant delays or discontinuation of development.

Regulatory Approval Obstacles: Even if clinical trials yield positive results, Galectin Therapeutics faces substantial uncertainty in obtaining necessary regulatory approvals from health authorities like the FDA. The approval process is rigorous, lengthy, and unpredictable, potentially preventing the drug from reaching the market.

Capital and Funding Dependence: Galectin Therapeutics is a clinical-stage biotechnology company that consumes significant cash for research and development. The company's future operations are dependent on its ability to raise additional capital, which may not be available on favorable terms or at all, potentially forcing a delay or halt to its programs.